SCHEMBL2453374

SCHEMBL2453374

COC(=O)c1ccc(S)c(OC)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.62
KMT2A Q03164 4/20 0.55
TDP1 Q9NUW8 1/20 0.52
CA1 P00915 4/20 0.52
CA2 P00918 4/20 0.52
CA12 O43570 3/20 0.52
CA7 P43166 3/20 0.52
CA9 Q16790 3/20 0.52
CA14 Q9ULX7 3/20 0.52
CA4 P22748 1/20 0.52
CA6 P23280 1/20 0.52
TPMT P51580 1/20 0.52
XDH P47989 1/20 0.52
HTT P42858 2/20 0.49
TSHR P16473 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
MEN1 O00255 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547243 0.85 MAPT (0.62) MAPTKMT2ATDP1CA1CA2
SCHEMBL11828207 0.85 CA1 (0.71) CA1CA2CA12CA7CA9
SCHEMBL6517455 0.83 LMNA (0.55) MAPTKMT2ACA1CA2CA12
SCHEMBL27616936 0.83 CA12 (0.46) MAPTKMT2ACA1CA2CA12
SCHEMBL27603935 0.83 HSD17B2 (0.69) MAPTKMT2ACA1CA2CA12
Veratric Acid Methyl Ester SCHEMBL29573244 0.82 MAPT (0.86) MAPTKMT2ACA1CA2CA12
SCHEMBL21383063 0.82 CA1 (0.57) MAPTKMT2ATDP1CA1CA2
Veratric Acid Methyl Ester SCHEMBL2050732 0.82 MAPT (0.86) MAPTKMT2ACA1CA2CA12
SCHEMBL15342989 0.82 PLK1 (0.53) MAPTKMT2ACA1CA2CA12
SCHEMBL6517172 0.81 LMNA (0.53) MAPTKMT2ACA1CA2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018081285-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-05-03 WO disclosed
US-9790213-B2 Imidazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2017-10-17 US disclosed
EP-1577350-B1 Method for production of halogen-containing phthalocyanine compound NIPPON CATALYTIC CHEM IND (JP) 2011-09-14 EP disclosed
US-7473777-B2 Method for production of halogen-containing phthalocyanine compound NIPPON SHOKUBAI CO., LTD. (JP) 2009-01-06 US disclosed
CN-1680380-A Method for production of halogen-containing phthalocyanine compound NIPPON CATALYTIC CHEM IND (JP) 2005-10-12 CN disclosed
EP-1577350-A1 Method for production of halogen-containing phthalocyanine compound Nippon Shokubai Co., Ltd. (JP) 2005-09-21 EP disclosed
US-20050203293-A1 Method for production of halogen-containing phthalocyanine compound NIPPON SHOKUBAI CO., LTD. (JP) 2005-09-15 US disclosed
EP-0523959-B1 Novel phthalocyanine compounds, production method thereof, and near infrared ray absorption materials containing the same NIPPON CATALYTIC CHEM IND (JP) 1999-10-13 EP disclosed
US-5359056-A Lightfastness, solvent solubility NIPPON SHOKUBAI CO., LTD. (JP) 1994-10-25 US disclosed
EP-0523959-A2 Novel phthalocyanine compounds, production method thereof, and near infrared ray absorption materials containing the same NIPPON SHOKUBAI CO., LTD. (JP) 1993-01-20 EP disclosed